P S Charifson

Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.

A. M. Myers, R. Baldessarini, P. Charifson, 1994, Journal of medicinal chemistry.

Improved scoring of ligand-protein interactions using OWFEG free energy grids.

P. Charifson, D. Pearlman, D A Pearlman, 2001, Journal of medicinal chemistry.

Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands.

J P Bowen, R. Mailman, P. Charifson, 1988, Journal of medicinal chemistry.

Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.

D E Nichols, R. Mailman, P. Charifson, 1994, Journal of medicinal chemistry.

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.

J. Lehmann, P. Charifson, L. Leesnitzer, 1998, Journal of medicinal chemistry.

Simulation of the solution structure of the H-ras p21-GTP complex.

T. Darden, L. Pedersen, P. Charifson, 1992, Biochemistry.

Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.

J P Bowen, R. Mailman, P. Charifson, 1989, Journal of medicinal chemistry.